AI assistant
UCB Share Issue/Capital Change 2022
4017_dirs_2022-06-24_71410d91-21b6-46eb-b928-b745a3da604f.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Disposal of own shares
Brussels (Belgium), 24 June 2022 – 20:00 (CEST) – Regulated information
In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:
| Date of transaction | Time | LTI Plan | Number of disposed UCB shares |
Price |
|---|---|---|---|---|
| 17 June 2022 | 10:42:48 | Stock Option Plan 2016 | 100 | € 67,24 |
| 20 June 2022 | 09:43:50 | Stock Option Plan 2013 | 200 | € 48,69 |
| 20 June 2022 | 13:31:57 | Stock Option Plan 2016 | 100 | € 67,24 |
| 21 June 2022 | 12:18:17 | Stock Option Plan 2016 | 100 | € 67,24 |
This press release is available on UCB SA/NV's website via the following link.
For further information, contact UCB:
Investor Relations Antje Witte T +32 2 559 94 14 [email protected]
Corporate Communications Laurent Schots T+32 2 559 92 64 [email protected]
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
